Home > Result Summaries: Compounds > GSK2118436 Result Summaries: GSK2118436 GSKStudy ID Phase Title Summary (Download) 113463 phase 1 An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects with BRAF Mutant Solid Tumors (0 citation(s)) 113683 phase 3 A Phase III randomized, open-label study comparing GSK2118436 to Dacarbazine (DTIC) in previously untreated subjects with BRAF mutation positive advanced (Stage III) or metastatic (Stage IV) melanoma (1 citation(s)) 113929 phase 2 BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain (1 citation(s))
